慢性肝炎病理评价分类系统的发展与未来

陈洋溢; 刘成海

doi:10.3969/j.issn.1001-5256.2018.05.037

慢性肝炎病理评价分类系统的发展与未来

DOI: 10.3969/j.issn.1001-5256.2018.05.037

1. 上海中医药大学附属曙光医院肝硬化科
2. 上海市中医临床重点实验室

详细信息

中图分类号: R575.1
计量
- 文章访问数: 1813
- HTML全文浏览量: 14
- PDF下载量: 386
- 被引次数: 0
出版历程
- 收稿日期: 2018-01-03
- 出版日期: 2018-05-20

Development and prospects of pathological classification systems for chronic hepatitis

Department of Liver Cirrhosis, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

摘要

摘要: 肝脏病理是慢性肝炎诊断的金标准。虽然目前有众多有效的无创诊断方法,但对于获取慢性肝炎的炎症及纤维化情况,肝脏病理仍然是最为直观可靠的方法。同时肝脏病理评价分类系统也在不断发展完善,以便更加准确地提供分级分期信息,指导临床与科研。通过文献复习回顾肝脏病理评价分类系统的发展历程,解读每一个主要评价分类系统的基本标准以及不足,并结合现状展望慢性肝炎病理评价分类系统的研究前景。
- 肝炎,慢性 /
- 病理学,临床 /
- 综述
Abstract: Liver pathology is the gold standard for the diagnosis of chronic hepatitis. Although there are many effective noninvasive diagnostic methods, liver pathology is still the most direct and reliable method for evaluating inflammation and fibrosis in patients with chronic hepatitis.The classification system for liver pathology has been also constantly changing, so as to provide more accurate information of grading and staging and to guide clinical and scientific research. This article reviews the development of classification systems for liver pathology, the basic criteria and disadvantages of each major classification system, and the prospects of pathological classification systems for chronic hepatitis.
- hepatitis, chronic /
- pathology, clinical /
- review

HTML全文

参考文献(35)

[1]MENGHINI G.One-second needle biopsy of the liver[J].Gastroenterology, 1958, 35 (2) :190-199.

[2]SHIHA G, IBRAHIM A, HELMY A, et al.Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis:a 2016 update[J].Hepatol Int, 2017, 11 (1) :1-30.

[3]European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Hiqado.EASL-ALEH clinical practice guide lines:non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol, 2015, 63 (1) :237-264.

[4]JANG W, YU SI, SINN DH, et al.Longitudinal change of liver stiffness by transient elestography in chronic hepatitis B patients treated with nucleos (t) ide analogue[J].Clin Res Hepatol Gastroenterol, 2014, 38 (2) :195-200.

[5]DESMET VJ, GERBER M, HOOFNAGLE JH, et al.Classification of chronic hepatitis:diagnosis, grading and staging[J].Hepatology, 1994, 19 (6) :1513-1520.

[6]LEEVY C, TYGSTRUP N.Standardization of nomenclature, diagnostic criteria, and diagnostic methodology[M].Washington DC:Government Printing Office, 1976:9.

[7]LOEWI G.Mechanism of cell and tissue damage produced by immuno reactions:second international symposium on immunopathology, Michigan, U.S.A., 1961[J].Immunology, 1963, 6 (3) :301.

[8]POWELL LW.The nature of cell death in piecemeal necrosis:is order emerging from chaos?[J].Hepatology, 1987, 4 (7) :794-796.

[9]CZAJA AJ, CARPENTER HA.Histologic findings in chronic hepatitis C with autoimmune features[J].Hepatology, 1979, 26 (2) :459-466.

[10]FRENCH SW, ENBOM ET.Piecemeal necrosis of the liver revisited a review[J].Exp Mol Pathol, 2014, 96 (3) :307-309.

[11]MATTSSON L, WEILAND O, GLAUMANN H.Application of a numerical scoring system for assessment of histological outcome in patients with chronic post-transfusion non-A, non-B hepatitis with or without antibodies to hepatitis C[J].Liver, 1990, 10 (5) :257-263.

[12]YANO M, KUMADA H, KAGE M, et al.The long-term pathological evolution of chronic hepatitis C[J].Hepatology, 1996, 23 (6) :1334-1340.

[13]POYNARD T, BEDOSSA P, OPOLON P.Natural history of liver fibrosis progression in patients with chronic hepatitis C[J].Lancet, 1997, 349 (9055) :825-832.

[14]COOKSLEY WG, BRADBEAR RA, ROBINSON W, et al.The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis[J].Hepatology, 1986, 6 (3) :345-348.

[15]CHEN TJ, LIAW YF.The prognostic significance of bridging hepatic necrosis in chronic type B hepatitis:a histopathologic study[J].Liver, 1988, 8 (1) :10-16.

[16]KERR JF, COOKSLEY WG, SEARLE J, et al.The nature of piecemeal necrosis in chronic active hepatitis[J].Lancet, 1979, 20 (2) :827-828.

[17]de GROOTE J, DESMET VJ, GEDIGK P, et al.A classification of chronic hepatitis[J].Lancet, 1968, 2 (7568) :626-628.

[18]KNODELL RG, ISHAK KG, BLACK WC, et al.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J].Hepatology, 1981, 1 (5) :431-435.

[19]SCHEUER PJ.Classification of chronic viral hepatitis:a need for reassessment[J].J Hepatol, 1991, 13 (3) :372-374.

[20]BATTS KP, LUDWIG J.Chronic hepatitis.An update on terminology and reporting[J].Am J Surg Pathol, 1995, 19 (12) :1409-1417.

[21]BEDOSSA P, POYNARD T.An algorithm for the grading of activity in chronic hepatitis C.The METAVIR Cooperative Study Group[J].Hepatology, 1996, 24 (2) :289-293.

[22]ISHAK K, BAPTISTA A, BIANCHI L, et al.Histological grading and staging of chronic hepatitis[J].J Hepatol, 1995, 22 (6) :696-699.

[23]SCHIFF ER, LEE SS, CHAO YC, et al.Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B[J].Clin Gastroenterol Hepatol, 2011, 9 (3) :274-276.

[24]TRABER PG, CHOU H, ZOMER E, et al.Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease[J].PLo S One, 2013, 8 (10) :e75361.

[25]LIAW YF.Reversal of cirrhosis:an achievable goal of hepatitis B antiviral therapy[J].J Hepatol, 2013, 59 (4) :880-881.

[26]KUTAMI R, GIRGRAH N, WANLESS IR, et al.The Laennec grading system for assessment of hepatic fibrosis:validation by correlation with wedged hepatic vein pressure and clinical features[J].Hepatology, 2000, 32 (4 Pt 2) :407A.

[27]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:who and why?[J].Liver Int, 2015, 35 (Suppl 1) :78-81.

[28]SUN Y, ZHOU J, WANG L, et al.New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J].Hepatology, 2017, 65 (5) :1438-1450.

[29]WANLESS IR, NAKASHIMA E, SHERMAN M.Regression of human cirrhosis.Morphologic features and the genesis of incomplete septal cirrhosis[J].J Arch Pathol Lab Med, 2000, 124 (11) :1599-1607.

[30]SETHASINE S, JAIN D, GROSZMANN RJ, et al.Quantitative histological-hemodynamic correlations in cirrhosis[J].Hepatology, 2012, 55 (4) :1146-1153.

[31]WANG Y, HOU JL.Fibrosis assessment:impact on current management of chronic liver disease and application of quantitative invasive tools[J].Hepatol Int, 2016, 10 (3) :448-461.

[32]XU S, WANG Y, TAI DC, et al.q Fibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J].J Hepatol, 2014, 61 (2) :260-269.

[33]ASSELAH T, MARCELLIN P, BEDOSSA P.Improving performance of liver biopsy in fibrosis assessment[J].J Hepatol, 2014, 61 (2) :193-195.

[34]STRUPLER M, PENA AM, HERNEST M, et al.Second harmonic imaging and scoring of collagen in fibrotic tissues[J].J Opt Express, 2007, 15 (7) :4054-4065.

[35]ROUSSELET MC, MICHALAK S, DUPRE F, et al.Sources of variability in histological scoring of chronic viral hepatitis[J].Hepatology, 2005, 41 (2) :257-264.

施引文献

资源附件(0)

访问统计